Donor Simvastatin Treatment Prevents Ischemia-Reperfusion and Acute Kidney Injury by Preserving Microvascular Barrier Function
Article first published online: 14 JUN 2013
© Copyright 2013 The American Society of Transplantation and the American Society of Transplant Surgeons
American Journal of Transplantation
Volume 13, Issue 8, pages 2019–2034, August 2013
How to Cite
Tuuminen, R., Nykänen, A. I., Saharinen, P., Gautam, P., Keränen, M. A. I., Arnaudova, R., Rouvinen, E., Helin, H., Tammi, R., Rilla, K., Krebs, R. and Lemström, K. B. (2013), Donor Simvastatin Treatment Prevents Ischemia-Reperfusion and Acute Kidney Injury by Preserving Microvascular Barrier Function. American Journal of Transplantation, 13: 2019–2034. doi: 10.1111/ajt.12315
- Issue published online: 26 JUL 2013
- Article first published online: 14 JUN 2013
- Manuscript Accepted: 7 APR 2013
- Manuscript Revised: 31 MAR 2013
- Manuscript Received: 13 SEP 2012
- Academy of Finland, the Sigrid Juselius Foundation
Additional supporting information may be found in the online version of this article at the publisher's web-site.
Figure S1. Simvastatin treated DA rat macrophages do not directly affect on allogenic T cell activation. As the potential cellular effects of donor simvastatin treatment are carried along with the transplanted kidney, the possible primary targets of donor simvastatin treatment are kidney tissue cells and passenger leukocytes within the transplant. Here we wanted to study whether the simvastatin treatment of DA rats affect on allogenic T cell priming. (A) Quantitative real-time PCR analysis of isolated macrophages from DA rats 2 h after simvastatin 5 mg/kg (p.o) or vehicle treatment. (B) Major MHC-mismatched WF rat T cells were cultured for 5 days together with isolated macrophages of simvastatin or vehicle-treated DA rats. Anti-CD3 stimulation was used to assure the viability of the cells and native and syngenic cells were used as negative controls. ELISpot analysis of T cell INF-γ production at 5 days showed similar T cell activation for simvastatin or vehicle treatment groups. (A) The results were normalized to GAPDH molecule numbers and are given as a ratio to mRNA in vehicle-treated macrophages. (A, B) Mean values of duplicate samples were used for data interpretation. N = 3/group. *p < 0.05.
Table S1. Relative mRNA levels after simvastatin treatment in kidney allografts at 6 h and 5 days.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.